Clinical Trial

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Study acronym: SOPRANO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
SOPRANO is a multi-centre phase II trial designed to assess the impact of SBRT with or without continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-08-10; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT05990192
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Royal Marsden NHS Foundation Trust
Conditions Ovarian Cancer Recurrent
Enrollment 42 participants
Start Date 2024-06-20
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13